Remlifanserin Falls Short in Phase 2 ADP Trial, but Secondary Signal Keeps Hope Alive
ACAD is trading near its 52-week low of $19.69 (14% above the low) on elevated volume (3.7× avg).
Summary
Remlifanserin missed its primary endpoint in the Phase 2 RADIANT study for Alzheimer's disease psychosis, but showed a nominally significant secondary endpoint and favorable safety. The company will continue Phase 3 with the 60 mg dose only.
Key Events · Product Development and Regulatory · ACAD
-
Primary Endpoint Missed
SAPS-H+D change of -12.6 for 60 mg remlifanserin vs -10.4 for placebo (effect size 0.26, p=0.0603), narrowly missing statistical significance.
-
Secondary Endpoint Positive
CGI-S-ADP change of -1.3 vs -0.9 for placebo (effect size 0.37, p=0.0077 nominal), with dose-response trend increasing through week 6.
-
Phase 3 Program Amended
Company will continue enrolling two ongoing Phase 3 studies with the 60 mg dose only, removing the 30 mg arm which showed minimal improvement.
-
Favorable Safety Profile
Adverse events, serious adverse events, and discontinuations similar to placebo; no QT prolongation signal and no deaths in treatment arms.
Analysis · ACAD · Life Sciences
The Phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis narrowly missed its primary endpoint (p=0.0603), yet delivered a nominally significant improvement on the key secondary endpoint (p=0.0077) and a favorable safety profile. Given the absence of approved therapies in this large market, the primary miss is a setback, but the secondary signal and dose-response trend justify continued investment. The company will proceed with Phase 3 development using only the 60 mg dose, dropping the 30 mg arm. The stock is likely to react negatively to the primary miss, though the secondary endpoint and safety data provide some support.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACAD was trading at $22.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $19.69 to $30.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.